 |
|
|
|
|
|
|
|
 |
Results for 'Drug Discovery Technology' |
|
|
| Title |
 |
Publication Date |
|
Price |
|
Relevance |
 |
|
|
|
|
Industrialization of Drug Discovery
|
May 2005 |
£80 |
44.5 % |
Neurogen Corporation
Premium Company Profile
|
January 2008 |
£265 |
36.5 % |
Translational Medicine - Drug Development Transformed? (Market Focus)
Drug Development Transformed? (Market Focus)
|
February 2007 |
£947 |
35 % |
Biopharmaceuticals: Biochemistry and Biotechnology
Second Edition
|
July 2003 |
£47.5 |
35 % |
Outlook for RNAi, 2007
siRNA and miRNA in biology, diagnostics and therapeutics
|
June 2007 |
£1495 |
33 % |
Drug Repositioning Strategies
Innovative Strategies To Boost Pipeline Productivity
|
June 2007 |
£1495 |
31.5 % |
Lexicon Pharmaceuticals Inc
Premium Company Profile
|
April 2008 |
£265 |
29 % |
Premium Company Profile Vertex Pharmaceuticals
|
October 2007 |
£265 |
28.5 % |
Cancer Biomarkers
Enhancing diagnostic, therapeutic and developmental strategies
|
May 2006 |
£2195 |
28.5 % |
Virtual Pharma
The Radical Route To Success
|
September 2008 |
£795 |
28.35 % |
Life Science Tools and Technologies for Bio-Pharma R&D
Instruments, Tech Platforms, Informatics and Market
|
March 2003 |
£1025 |
27.3 % |
Cardiovascular Biomarkers: Players, products and prospects (Volume III)
|
August 2008 |
£595 |
26.95 % |
Burger's Medicinal Chemistry and Drug Discovery
6 Volume Set
|
March 2003 |
£1331 |
25.9 % |
Directed Molecular Evolution
Product lifecycle management for biologics
|
May 2006 |
£4000 |
25.5 % |
Drug Delivery in Cancer
Technologies, Markets and Companies
|
December 2008 |
£2055 |
25.5 % |
Cell Based Label-Free Detection Trends 2007
|
January 2008 |
£1540 |
25.2 % |
Cancer Drug Resistance
2008
|
September 2008 |
£1675 |
25 % |
Strategic Outlook on Protein Kinase Inhibitors in Oncology
|
February 2006 |
£1780 |
24.5 % |
Isis Pharmaceuticals Inc
Premium Company Profile
|
December 2007 |
£265 |
24 % |
RNA Interference for Drug R&D
Applications, Alliances, Companies and WW Market to 2011
|
July 2007 |
£1775 |
23.1 % |
Momenta Pharmaceuticals Inc
Premium Company Profile
|
December 2007 |
£265 |
23 % |
Combinatorx Incorporated
Premium Company Profile
|
December 2007 |
£265 |
23 % |
Becton, Dickinson and Co
Premium Company Profile
|
April 2008 |
£265 |
23 % |
Drug Discovery Handbook
|
July 2005 |
£94.5 |
22.75 % |
Worldwide Cell Based Screening & Analysis Market for Bio-Pharma Drug Discovery
Equipment, Technologies and Companies, 2006-2011
|
January 2007 |
£1125 |
22.05 % |
Drug Repositioning
A market analysis
|
March 2006 |
£1095 |
22 % |
Handbook of Genome Research
Genomics, Proteomics, Metabolomics, Bioinformatics, Ethical and Legal Issues, Two Volumes
|
June 2005 |
£175 |
21.7 % |
Biochips
Industry forecasts for 2012 & 2017
|
October 2008 |
£3150 |
21.35 % |
Innovation in Drug Delivery
The future of nanotechnology and non-invasive protein delivery
|
November 2006 |
£1495 |
21 % |
Cancer Biomarkers: Players, products and prospects (Volume I)
|
August 2008 |
£595 |
21 % |
High-Content Analysis 2007
|
April 2007 |
£1540 |
21 % |
Emerging Markets for Microfluidic Applications
|
June 2007 |
£3640 |
21 % |
Fluorescence Lifetime Trends 2007
|
March 2007 |
£1540 |
20.65 % |
RNAi 2004
Strategic Opportunities
|
January 2004 |
£1995 |
20.5 % |
Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
|
June 2008 |
£2025 |
20 % |
China Bio-Pharma Profiles 2005
|
November 2005 |
£975 |
20 % |
Early Toxicology
Markets and Approaches
|
June 2007 |
£2390 |
19.95 % |
Advances in Biopharmaceutical Technology in China
|
September 2006 |
£3410 |
19.6 % |
Drug Discovery Tools for High-Content Analysis
|
July 2007 |
£1370 |
19.6 % |
Cancer, CNS & Cardiovascular Biomarkers: Players, products and prospects
|
August 2008 |
£1495 |
19.6 % |
The Future of Monoclonal Antibodies Therapeutics
Innovation in antibody engineering, key growth strategies and forecasts to 2011
|
July 2006 |
£1495 |
19.25 % |
Nanotechnology
Revolutionizing R&D to Develop Smarter Therapeutics and Diagnostics
|
January 2008 |
£1995 |
19.25 % |
Molecular Diagnostics Markets
|
September 2008 |
£2325 |
19 % |
The Future of Metabolomics
Building competitive advantage in drug discovery, clinical development and diagnostics
|
August 2006 |
£1495 |
18.9 % |
The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics
|
April 2008 |
£2055 |
18.9 % |
Licensing Strategies - Examining Todays Pharmaceutical Licensing Trends
|
November 2007 |
£7600 |
18.9 % |
Proteomics
|
June 2003 |
£3500 |
18.55 % |
Microarray Markets
|
September 2008 |
£1370 |
18.55 % |
Innovations in CNS
Novel therapeutics and future R&D strategies
|
January 2007 |
£1495 |
18.5 % |
Dyax Corp - SWOT Analysis
|
March 2008 |
£66 |
18.5 % |
Therapeutic/Diagnostic Devices for Neurological Disorders
|
March 2007 |
£3320 |
18.2 % |
Transition Therapeutics Inc
Premium Company Profile
|
April 2008 |
£265 |
18 % |
India: Pharmaceutical and biotechnology opportunities
|
April 2006 |
£600 |
17.85 % |
Commercial Opportunities from Biomarkers
Transforming drug discovery, clinical development and molecular diagnostic
|
May 2006 |
£1495 |
17.85 % |
Winning R&D Productivity Strategies
Exploiting innovation, licensing and outsourcing opportunities
|
October 2006 |
£1495 |
17.85 % |
Tissue Microarrays
Market Assessment and Opportunities
|
May 2004 |
£1995 |
17.85 % |
Personalized Medicine
|
August 2007 |
£1370 |
17.85 % |
Bioinformatics Report
The forecasts and future of the market 2006-2011
|
October 2006 |
£1499 |
17.5 % |
Streamlining Information in the Pharmaceutical Industry with PLM (Review Report)
|
August 2007 |
£1795 |
17.15 % |
Biopartnering Strategies
Maximizing returns from biotechnology deal-making
|
December 2006 |
£1495 |
17 % |
Bioinformatics Opportunities
Business models, trends and future challenges
|
May 2004 |
£2500 |
16.8 % |
Innovations in Bioinformatics
Emerging Tools for Drug Discovery and Development
|
January 2008 |
£1995 |
16.8 % |
Clinical Trial Supply
|
January 2007 |
£595 |
16.8 % |
Bioinformatics
Technical Status and Market Prospects
|
August 2005 |
£3320 |
16.8 % |
Microplate Mixing Trends 2007
|
September 2007 |
£1540 |
16.8 % |
In Silico ADME/Tox Products Market 2006
|
June 2006 |
£1540 |
16.8 % |
Pharmaceutical Contract Manufacturing and Research
|
May 2005 |
£3320 |
16.45 % |
Biologic Imaging Reagents
Technologies and Global Markets
|
December 2008 |
£2150 |
16.45 % |
Protein Biochips
|
April 2003 |
£2025 |
16.45 % |
Stakeholder Opinions
Novel Therapeutic Approaches in Cardiovascular Medicine - Lack of Market Prospects for Biologics Expose An Opportunity for Cell and Gene Therapies
|
July 2008 |
£3800 |
16.45 % |
Biomarkers
The Expanding Global Market
|
November 2007 |
£3320 |
16.1 % |
Next Generation Protein Engineering and Drug Design
Strategies to boost efficacy and improve drug delivery
|
February 2007 |
£1495 |
16.1 % |
Competitive Outlook on Non-Antibody Based Cancer Vaccines
|
August 2006 |
£1780 |
16.1 % |
Nanotechnology Opportunity Report, The
|
June 2003 |
£1330 |
16.1 % |
How to React to Parallel Trade
|
January 2007 |
£1095 |
16 % |
Genomics World Markets
|
May 2008 |
£2325 |
15.75 % |
Bioinformatics Markets
Strategies, Business Models and Trends for the Future
|
June 2006 |
£2325 |
15.4 % |
Emerging Opportunities in Cancer Nanomedicine
|
August 2006 |
£995 |
15.4 % |
Innovative Clinical Trial Design and Management
Trends, Success Stories and Impact upon R&D Budgets
|
May 2008 |
£1995 |
15.05 % |
Biomarkers: The Future of Next-Generation Drug R&D
|
September 2008 |
£1775 |
15.05 % |
Cell-Based Diagnostics: Technology, Applications, and Markets
2nd Edition
|
November 2007 |
£2735 |
15.05 % |
Biomarkers
|
January 2008 |
£2270 |
15.05 % |
Future of RNAi Therapeutics, The
Drug Pipelines and Prospects
|
September 2008 |
£1995 |
14.7 % |
Innovations and Trends in Clinical Trials
Microdosing (Phase 0 Trials), Adaptive Trials, Phase IV Trials and the Role of Information Technology
|
March 2007 |
£1540 |
14.7 % |
Who's Developing What in New Cancer Drugs 2006?
|
November 2007 |
£495 |
14.5 % |
Medical Nanotechnology Markets
|
September 2008 |
£2325 |
14.35 % |
Gene Expression Reagents Markets
|
April 2007 |
£1370 |
14.35 % |
Market for Bioengineered Protein Drugs; The
|
January 2007 |
£3320 |
14.35 % |
Innovative And Targeted Cancer Therapies
Key Technologies, New Applications And Leading Players
|
July 2007 |
£1495 |
14 % |
Proteomics
Technologies, Markets and Companies
|
December 2008 |
£2395 |
13.65 % |
ADME/TOX Technologies
|
January 2008 |
£2000 |
13.65 % |
Triple Analysis: Apoptosis Agents, Antibodies and Vaccines in Oncology
|
December 2006 |
£3150 |
13.65 % |
Multiplexed Diagnostics 2008
|
May 2008 |
£2350 |
13.3 % |
RNAi
Technologies, Markets and Companies
|
December 2008 |
£2055 |
13.3 % |
High Throughput Screening
|
January 2008 |
£2105 |
13.3 % |
Epigenomics
Emerging Opportunities in Biomarkers, Diagnostics and Therapeutics
|
March 2007 |
£3320 |
13.3 % |
Contract Pharmaceutical Manufacturing, Research, and Packaging
|
August 2007 |
£3320 |
13.3 % |
From blockbuster to nichebuster
Niche therapies drive future drugs growth and incentivize R&D investment over sales spending
|
July 2006 |
£1055 |
12.95 % |
Early Stage and Discovery Deals
Strategy, Structure and Payment Terms 2nd Edition
|
January 2007 |
£1350 |
12.95 % |
Companion Diagnostics in Personalized Medicine and Cancer Therapy
|
April 2008 |
£2325 |
12.95 % |
Opportunities in Stem Cell Research and Commercialization
Technology advances, regulatory impact and key players
|
April 2006 |
£1495 |
12.6 % |
Impact of Pharmacogenomics on Public Healthcare Policy
Educating Patients, Payors and Healthcare Providers
|
March 2008 |
£1995 |
12.6 % |
Disposable Syringe Markets
Trends, Industry Participants, Product Overviews and Market Drivers
|
September 2008 |
£1370 |
12.6 % |
DNA Sequencing and PCR Markets
|
July 2008 |
£2325 |
12.25 % |
Pharmacogenomics: New Technologies
In the Development of Personalized Therapies
|
August 2005 |
£3320 |
12.25 % |
Nuclear Cardiology Markets
|
December 2007 |
£1370 |
12.25 % |
hERG Screening
|
January 2008 |
£2020 |
11.9 % |
Indian Pharmaceutical Industry, The:
|
March 2005 |
£3335 |
11.55 % |
Preclinical Cancer Therapeutics 2007
Decoding Next Generation Drug Targets for Market Success
|
December 2006 |
£1600 |
11.55 % |
Biomarkers & Related Tests for Molecular Diagnostics & Pharma/ Biotech R&D
Companies, Products & Worldwide Market, 2004-2009
|
July 2005 |
£1295 |
11.55 % |
Nanotechnology in Life Science Applications
|
October 2005 |
£3320 |
11.2 % |
Nanomedicine 2006-2011
|
June 2006 |
£1499 |
11.2 % |
Global Clinical Trial Business Report & Analysis 2008-2018
|
July 2008 |
£1499 |
10.85 % |
RNA Interference Markets
|
December 2008 |
£2325 |
10.85 % |
Triple Analysis: Protein Kinase Inhibitors, Antibodies and Vaccines in Oncology
|
August 2006 |
£3150 |
10.5 % |
Neurodegenerative Disease Drug Market Analysis and Forecasts 2007
|
June 2007 |
£1999 |
10.5 % |
Targeted Therapies in Oncology
A World Review
|
December 2006 |
£4515 |
10.5 % |
Triple Progress Analysis: Lymphoma Therapeutics, Protein Kinase Inhibitors & Therapeutic Antibodies
|
May 2006 |
£3150 |
10.5 % |
Metabolomics
|
January 2008 |
£1890 |
10.5 % |
DNA Sequencing
|
February 2008 |
£3080 |
10.15 % |
Fastest Growing Biotechnology Companies, The
Growth Strategies, Comparative Analyses and Company Profiles
|
March 2008 |
£1995 |
10.15 % |
Triple Analysis: Melanoma Therapeutics, Antibodies and Vaccines in Oncology
|
August 2006 |
£3150 |
10.15 % |
The Market for In Vitro Toxicology Testing
|
March 2007 |
£3320 |
10.15 % |
Cancer Personalized Medicine 2008
|
July 2008 |
£2425 |
10 % |
In Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
9.8 % |
Personalized Medicine
scientific & commercial aspects
|
December 2008 |
£2735 |
9.8 % |
Mergers & Acquisitions in Pharmaceuticals
When and how
|
February 2000 |
£165 |
9.8 % |
In-Vitro Diagnostics Market Report & Analysis 2008-2023
|
June 2008 |
£1499 |
9.8 % |
Chemotherapy Market Insights, 2006-2016
A Critical Analysis of Cancer Research, Treatments, Pipelines, and Commercial Opportunities
|
April 2006 |
£1900 |
9.45 % |
Cytogenetics
technologies,markets and companies
|
December 2008 |
£1370 |
9.45 % |
Dynamic Antibody Industry
|
August 2005 |
£3320 |
9.45 % |
Animal Biotechnology
Technologies, Markets and Companies
|
December 2008 |
£1710 |
9.1 % |
SNP Genotyping and Analysis Markets
|
June 2008 |
£2735 |
8.75 % |
Modern Biopharmaceuticals
Design, Development and Optimization, 4 Volumes
|
September 2005 |
£440 |
8.4 % |
A Practical Guide to Biopharmaceutical Manufacturing
|
January 2006 |
£1095 |
8.4 % |
How Drugs Are Developed
3rd Edition
|
January 2007 |
£1095 |
8.05 % |
Apoptosis
|
January 2008 |
£1985 |
8.05 % |
The Executive Guide to Molecular Imaging
|
July 2007 |
£595 |
8.05 % |
Taq Wars; The
Competitive Intelligence on How to Survive
|
November 2005 |
£3080 |
8.05 % |
Global Market for Antimicrobials and Antifungals; The
Challenging Resistance to 2016
|
December 2006 |
£1600 |
7.7 % |
U.S. Market for Gastrointestinal Pharmaceuticals
|
September 2005 |
£3320 |
7.7 % |
Cell Therapy
Technologies, Markets and Companies
|
December 2008 |
£3080 |
7.35 % |
Molecular Diagnostics
Technologies, Markets and Companies
|
December 2008 |
£3080 |
7 % |
Cell Therapy Markets
|
July 2007 |
£2325 |
7 % |
Indian Pharmaceutical Industry
|
July 2008 |
£2325 |
7 % |
Live-Licensing & In-life Testing
R&D Processes and Regulation for New Drugs, 2008-2020
|
January 2008 |
£1499 |
7 % |
Alzheimer's disease
New drugs, markets and companies
|
December 2008 |
£1915 |
7 % |
World Market for Molecular Diagnostics, The
|
January 2009 |
£2735 |
6.65 % |
Boston Scientific Medical Device Company Intelligence Report
|
October 2006 |
£395 |
6.3 % |
Nitric Oxide
Therapeutics, Markets and Companies
|
December 2008 |
£1915 |
5.95 % |
PAREXEL's Bio/Pharma R&D Statistical Sourcebook 2008/2009
|
June 2008 |
£290 |
4.9 % |
Parexel's Pharmaceutical R&D Statistical Sourcebook 2007/2008
|
May 2007 |
£290 |
4.55 % |
|
|
|
|
